Gender | Age
Item
men ≥ 18 years of age
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Antiandrogen therapy Prostate carcinoma
Item
history of prostate cancer treated with androgen deprivation
boolean
C0279492 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
Serum testosterone measurement
Item
serum testosterone levels <50 ng/ml
boolean
C0428413 (UMLS CUI [1])
Neoplasm Metastasis Asymptomatic | Neoplasm Metastasis Minimal Symptomatic
Item
established asymptomatic or minimally symptomatic metastasis
boolean
C0027627 (UMLS CUI [1,1])
C0231221 (UMLS CUI [1,2])
C0027627 (UMLS CUI [2,1])
C0547040 (UMLS CUI [2,2])
C0231220 (UMLS CUI [2,3])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status≤2
boolean
C1520224 (UMLS CUI [1])
Imaging Agreement | Protocol Compliance
Item
accept the terms of the imaging modalities and performance at pre-established time points as described in the protocol and consent
boolean
C0079595 (UMLS CUI [1,1])
C0680240 (UMLS CUI [1,2])
C0525058 (UMLS CUI [2])
Immune monitoring Agreement | Blood drawing Agreement | Protocol Compliance
Item
accept the terms for immune-monitoring blood drawing and performance at pre-established time points as described in the protocol and consent
boolean
C0026428 (UMLS CUI [1,1])
C0680240 (UMLS CUI [1,2])
C0190979 (UMLS CUI [2,1])
C0680240 (UMLS CUI [2,2])
C0525058 (UMLS CUI [3])
Steroids | Prednisone U/day | Hydrocortisone U/day | Zytiga | Ketoconazole | Combined Modality Therapy
Item
patients that are on steroids (prednisone up to 10mg daily or hydrocortisone 20 mg daily) alone or in combination with zytega or ketoconazole prior to enrollment are eligible
boolean
C0038317 (UMLS CUI [1])
C0032952 (UMLS CUI [2,1])
C0456683 (UMLS CUI [2,2])
C0020268 (UMLS CUI [3,1])
C0456683 (UMLS CUI [3,2])
C3153774 (UMLS CUI [4])
C0022625 (UMLS CUI [5])
C0009429 (UMLS CUI [6])
Steroids Chronic condition | Prednisone U/day | Dexamethasone U/day | Fludrocortisone Oral Product U/day
Item
patients that are on steroids for an underlying chronic condition are eligible. (prednisone up to 10 mg daily, dexamethasone <2 mg daily or fludrocortisone 0.1 mg daily orally)
boolean
C0038317 (UMLS CUI [1,1])
C4315615 (UMLS CUI [1,2])
C0032952 (UMLS CUI [2,1])
C0456683 (UMLS CUI [2,2])
C0011777 (UMLS CUI [3,1])
C0456683 (UMLS CUI [3,2])
C3214614 (UMLS CUI [4,1])
C0456683 (UMLS CUI [4,2])
Chemotherapy | Therapeutic radiology procedure
Item
chemotherapy or radiation therapy treatment within 21 days of sipuleucel-t
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
ECOG performance status
Item
ecog performance status >2
boolean
C1520224 (UMLS CUI [1])
sipuleucel-T
Item
prior treatment with sipuleucel-t
boolean
C1706668 (UMLS CUI [1])
Cancer Other Primary | Curative treatment Absent | Exception Basal cell carcinoma | Exception Squamous cell carcinoma of skin
Item
patients with a history of another primary malignancy within the last 2 years that was not curatively treated, excluding basal or squamous cell carcinoma of the skin
boolean
C1707251 (UMLS CUI [1,1])
C0205225 (UMLS CUI [1,2])
C1273390 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0553723 (UMLS CUI [4,2])
HIV Seropositivity | Hepatitis C positive
Item
patients with known positivity for human immunodeficiency virus (hiv) or hepatitis c; baseline testing for hiv and hepatitis c is not required
boolean
C0019699 (UMLS CUI [1])
C1112419 (UMLS CUI [2])
Treatment Compliance Lacking | Informed Consent Unable
Item
patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent
boolean
C4319828 (UMLS CUI [1,1])
C0332268 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2,1])
C1299582 (UMLS CUI [2,2])
Compression of spinal cord
Item
active spinal cord compression.
boolean
C0037926 (UMLS CUI [1])